Table 3.
ROC AUC and sensitivity at fixed specificity 75% for each biomarker and combinations
| B versus BOT ROC AUC (95% CI) | B versus M stage I ROC AUC (95% CI) | B versus all M ROC AUC (95% CI) | Sensitivity | |
|---|---|---|---|---|
| Cyst fluid | ||||
| GROa | 0.74 (0.66–0.83) | 0.67 (0.56–0.78) | 0.67 (0.60–0.75) | 50 |
| IL-8 | 0.80 (0.71–0.89) | 0.73 (0.62–0.84) | 0.73 (0.66–0.79) | 54 |
| MCP-1 | 0.81 (0.71–0.92) | 0.68 (0.57–0.78) | 0.61 (0.54–0.69) | 31 |
| CA125 + GROa | 0.80 (0.73–0.88) | 0.76 (0.65–0.87) | 0.86 (0.81–0.92) | 83 |
| CA125 + GROa + IL8 + MCP-l | 0.86 (0.79–0.94) | 0.77 (0.66–0.88) | 0.87 (0.82–0.93) | 85 |
| Serum | ||||
| GROa | 0.61 (0.49–0.74) | 0.45 (0.34–0.56) | 0.71 (0.63–0.78) | 58 |
| IL-8 | 0.47 (0.33–0.60) | 0.66 (0.55–0.77) | 0.76 (0.70–0.83) | 66 |
| MCP-1 | 0.52 (0.38–0.66) | 0.56 (0.46–0.66) | 0.50 (0.42–0.59) | 29 |
| CA125 + GROa + IL8 + MCP-l | 0.78 (0.67–0.89) | 0.76 (0.65–0.86) | 0.88 (0.82–0.93) | 77 |
| CA125 | 0.78 (0.67–0.89) | 0.76 (0.65–0.86) | 0.88 (0.82–0.93) | 86 |
B, Benign; BOT, Borderline; M, Malignant ovarian tumors; ROC, receiver operator characteristic; AUC, area under the curve; MCP-1, monocyte chemoattractant protein-1.